Monday 8/26 Insider Buying Report: ICPT, DFIN (Nasdaq.com)
On Thursday, Intercept Pharmaceuticals’ Director, Srinivas Akkaraju, made a $4.5M buy of ICPT, purchasing 67,784 shares at a cost of $66.37 each. Investors have the opportunity to bag ICPT even cheaper than Akkaraju did, with shares changing hands as low as $61.10 in trading on Monday which is 7.9% under Akkaraju’s purchase price. Intercept Pharmaceuticals is trading up about 0.9% on the day Monday. This purchase marks the first one filed by Akkaraju in the past twelve months. And at Donnelley Financial Solutions, there was insider buying on Thursday, by Director Jeffrey Jacobowitz who purchased 314,057 shares at a cost of $11.42 each, for a total investment of $3.59M. This buy marks the first one filed by Jacobowitz in the past year. Donnelley Financial Solutions is trading up about 6% on the day Monday.
Procter & Gamble Co (PG) CEO – Fabric & Home Care Shailesh Jejurikar Sold $919,822 of Shares (Guru Focus)
CEO – Fabric & Home Care of Procter & Gamble Co, Shailesh Jejurikar, sold 7,727 shares of PG on 08/26/2019 at an average price of $119.04 a share. The total sale was $919,822. Procter & Gamble Co is a consumer goods company. The firm markets its products internationally through various channels which include mass merchandisers, grocery stores, membership club stores, drug stores, and department stores. Procter & Gamble Co has a market cap of $299.07 billion; its shares were traded at around $119.52 with a P/E ratio of 87.89 and P/S ratio of 4.58. The dividend yield of Procter & Gamble Co stocks is 2.44%.
The EVP of Spire Inc (NYSE: SR) is Buying Shares (Analyst Ratings)
Today, the EVP of Spire Inc (SR), Steven Rasche, bought shares of SR for $49.88K. Following this transaction Steven Rasche’s holding in the company was increased by 100% to a total of $146.2K. The company has a one-year high of $87.13 and a one-year low of $70.53. SR’s market cap is $4.07B and the company has a P/E ratio of 21.32. Currently, Spire Inc has an average volume of 293.23K.
Notable Insider Buys In The Past Week: Sunrun, W.R. Grace (Benzinga)
Sunrun: Last week, Sunrun Inc RUN 2.69% 10% owner Tiger Global Management acquired 640,000 shares of this solar energy systems installer. At prices ranging from $15.43 to $16.13 per share, those transactions totaled more than $10.10 million. That brought the investment firm’s stake up to almost 14.21 million shares. KeyBanc just initiated bullish coverage on Sunrun and other solar stocks after the recent sell-off. Sunrun shares are down more than 18% this month and closed most recently at $14.66, below the above purchase price range. The stock has traded as high as $21.42 per share in the past 52 weeks.
YS Jaganmohan Reddy Government Finds Insider Trading in Amaravati Capital Land Deals (MumbaiMirror.IndiaTimes.com)
Amaravati: Amid widespread rumours that Andhra Pradesh capital would be shifted out of Amaravati, urban development minister Botsa Satyanarayana has made a sensational revelation that insider trading had taken place in the capital land dealings. “We have complete and authentic information about land dealings in Amaravati. Insider trading had taken place. We will make the details public shortly,” he said in Vijayawada. Responding to the claim of former Union Minister YS (Sujana) Chowdary, who recently joined the BJP, that he does not have lands in Amaravati, the minister said, “We are ready to prove his claims wrong with documentary proof.”
Arcturus Therapeutics Holdings Inc (ARCT) CFO Andy Sassine Bought $109,000 of Shares (Guru Focus)
CFO of Arcturus Therapeutics Holdings Inc, Andy Sassine, bought 10,000 shares of ARCT on 08/23/2019 at an average price of $10.9 a share. The total cost of this purchase was $109,000. Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases. Arcturus Therapeutics Holdings Inc has a market cap of $142.995 million; its shares were traded at around $10.90 with and P/S ratio of 6.20. Arcturus Therapeutics Holdings Inc had annual average EBITDA growth of 27.70% over the past five years. GuruFocus has detected 2 severe warning signs with Arcturus Therapeutics Holdings Inc.